A study on the effects of eicosapentaenoic acid (EPA) on arteriosclerosis in hemodialysis patients with percutaneous coronary intervention (PCI)
Not Applicable
Recruiting
- Conditions
- Dialysis patients who have been subjected to PCI.
- Registration Number
- JPRN-UMIN000002653
- Lead Sponsor
- agoya Kyoritsu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) A history of hypersensitivity to highly purified EPA preparations. 2) Have had the onset of stroke within the past 6 months. 3) Left ventricular ejection fraction below 40%. 4) Are currently pregnant or may be pregnant. 5) Suffering from hemorrhage (e.g., hemophilia, capillary fragility, gastrointestinal hemorrhage, urinary tract hemorrhage, hemoptysis and vitreous hemorrhage). 6) A peptic ulcer. 7) Extremely poor bile secretion or severe hepatic dysfunction. 8) Others judged to be inappropriate to participate in the current study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Restenosis rate one year after the treatment TVR one year after the treatment MACE [death, non-fatal myocardial infarction, stroke, revascularization (endovascular treatment or bypass surgery)]
- Secondary Outcome Measures
Name Time Method Improvement in IMT and CAVI as seen in comparison with before and after EPA administration